Sermonix

SMX 18-001

NCT03781063

JCP087

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer with an ESR1 Mutation

Status:

Recruiting

26459-200.png

II

Phase

Line of Therapy.png

2nd+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

ER+, HER2-, ESR1

Investigational

Product

Lasofoxifene

Selective modulator of the estrogen receptor (SERM) (p.o.)

Treatment Arms

o Experimental: Lasofoxifene

o Active Comparator: Fulvestrant